X
9.21
0.08 (0.88%)
| Previous Close | 9.13 |
| Open | 9.29 |
| Volume | 1,719,404 |
| Avg. Volume (3M) | 2,536,278 |
| Market Cap | 1,487,234,176 |
| Price / Earnings (Forward) | 22.17 |
| Price / Sales | 3.82 |
| Price / Book | 3.34 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -20.25% |
| Operating Margin (TTM) | -5.14% |
| Diluted EPS (TTM) | -0.290 |
| Quarterly Revenue Growth (YOY) | 47.90% |
| Current Ratio (MRQ) | 1.72 |
| Operating Cash Flow (TTM) | -26.71 M |
| Levered Free Cash Flow (TTM) | -5.90 M |
| Return on Assets (TTM) | -3.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Xeris Biopharma Holdings, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.7
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.70 |
|
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.19% |
| % Held by Institutions | 54.46% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Oppenheimer, 95.44%) | Buy |
| Median | 10.00 (8.58%) | |
| Low | 8.00 (Piper Sandler, -13.14%) | Hold |
| Average | 12.00 (30.29%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 7.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2025 | 10.00 (8.58%) | Buy | 7.43 |
| Oppenheimer | 07 Nov 2025 | 18.00 (95.44%) | Buy | 7.43 |
| 29 Oct 2025 | 18.00 (95.44%) | Buy | 9.62 | |
| Piper Sandler | 07 Nov 2025 | 8.00 (-13.14%) | Hold | 7.43 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HECHT BETH | - | 6.96 | -16,667 | -116,002 |
| Aggregate Net Quantity | -16,667 | |||
| Aggregate Net Value ($) | -116,002 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 6.96 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HECHT BETH | Officer | 01 Dec 2025 | Automatic sell (-) | 16,667 | 6.96 | 116,002 |
| Date | Type | Details |
|---|---|---|
| 01 Dec 2025 | Announcement | Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application |
| 06 Nov 2025 | Announcement | Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 |
| 23 Oct 2025 | Announcement | Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 03 Oct 2025 | Announcement | Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |